James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew
{"title":"问卷筛选试验在评估澳大利亚悉尼化脓性汗腺炎患病率中的诊断准确性。","authors":"James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew","doi":"10.1159/000540455","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.</p><p><strong>Methods: </strong>The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.</p><p><strong>Results: </strong>A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).</p><p><strong>Conclusions: </strong>This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233957/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.\",\"authors\":\"James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew\",\"doi\":\"10.1159/000540455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.</p><p><strong>Methods: </strong>The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.</p><p><strong>Results: </strong>A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).</p><p><strong>Conclusions: </strong>This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.</p>\",\"PeriodicalId\":11185,\"journal\":{\"name\":\"Dermatology\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233957/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000540455\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540455","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.
Methods: The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.
Results: A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).
Conclusions: This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.
期刊介绍:
Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.